Miura S, Ideishi M, Sakai T, Motoyama M, Kinoshita A, Sasaguri M, Tanaka H, Shindo M, Arakawa K
Department of Internal Medicine, School of Medicine, Fukuoka University, Japan.
J Hypertens. 1994 Oct;12(10):1177-81.
We postulated a 'kinin-tensin system' in which angiotensin II (Ang II) is cleaved by one or more serine protease independent of renin or angiotensin converting enzyme (ACE). The aim was to determine whether this alternative Ang II-forming pathway by serine proteases participates in the rise in plasma levels of Ang II during exercise in humans.
The study consisted of two double-blind crossover experiments. in experiment 1 six healthy volunteers who had been taking either placebo (group P) or the ACE inhibitor captopril (150 mg/day for 3 days; group C) performed a cycle ergometer graded exercise test at four different exercise intensities: stage 1, half of the intensity at the blood lactate threshold (WLT); stage 2, the intensity at WLT; stage 3, the intensity at 4 mmol/l blood lactate; and stage 4, an intensity between stage 3 and maximum intensity. In experiment 2 the same volunteers took captopril (150 mg/day for 3 days) and performed exercise at an intensity corresponding to 90% of the 4 mmol/l blood lactate intensity for 30 min during intravenous drip injection of a serine protease inhibitor, nafamostat [NAF; 0.2 mg/kg per h; NAF(+) group] or saline [NAF(-) group].
In experiment 1 plasma Ang II levels increased from at rest to after exercise in both groups P and C. Although there was a significant treatment effect, captopril did not significantly alter the exercise-induced changes in Ang II level. In experiment 2 the increase in Ang II level after 30 min exercise in the NAF(+) group was significantly lower than in the NAF(-) group.
These results suggest the presence of an alternative Ang II-forming pathway independent of ACE, and that one or more NAF-sensitive serine protease is responsible, at least partly, for generating Ang II during exercise.
我们推测存在一种“激肽 - 紧张素系统”,其中血管紧张素II(Ang II)由一种或多种丝氨酸蛋白酶裂解产生,该过程独立于肾素或血管紧张素转换酶(ACE)。本研究旨在确定这种由丝氨酸蛋白酶介导的Ang II生成途径是否参与人类运动期间血浆Ang II水平的升高。
本研究包括两个双盲交叉实验。在实验1中,6名健康志愿者分别服用安慰剂(P组)或ACE抑制剂卡托普利(150毫克/天,共3天;C组),并在四种不同运动强度下进行自行车测力计分级运动测试:第1阶段,血乳酸阈值(WLT)强度的一半;第2阶段,WLT强度;第3阶段,血乳酸浓度为4毫摩尔/升时的强度;第4阶段,第3阶段强度与最大强度之间的强度。在实验2中,相同的志愿者服用卡托普利(150毫克/天,共3天),并在静脉滴注丝氨酸蛋白酶抑制剂那法莫司他[NAF;0.2毫克/千克/小时;NAF(+)组]或生理盐水[NAF(-)组]期间,以相当于血乳酸浓度为4毫摩尔/升时强度的90%进行30分钟的运动。
在实验1中,P组和C组的血浆Ang II水平均从静息状态升高至运动后。尽管存在显著的治疗效果,但卡托普利并未显著改变运动诱导的Ang II水平变化。在实验2中,NAF(+)组运动30分钟后Ang II水平的升高显著低于NAF(-)组。
这些结果表明存在一条独立于ACE的Ang II生成途径,并且一种或多种对NAF敏感的丝氨酸蛋白酶至少部分负责运动期间Ang II的生成。